BC Week In Review | Feb 9, 2015
Clinical News

BJI InoPlex regulatory update

Diaxonhit received CE Mark approval for BJI InoPlex test to diagnose prosthetic bone and joint infections. The company said it will launch the non-invasive multi-parameter serologic test in France on Feb. 9. Diaxonhit (Euronext:ALEHT), Paris,...
BC Innovations | Oct 23, 2014
Cover Story

Diagnosing resistance

It might be a day late and a dollar short, but the U.S. government is finally getting around to addressing what many experts think is the big unserved need in antibiotic resistance-new diagnostics. Faster, more...
BC Week In Review | Oct 6, 2014
Clinical News

BJI InoPlex: Pivotal trial completed enrollment

Diaxonhit completed enrollment of 470 patients, including 200 with infected prostheses, in an open-label, French validation trial of BJI InoPlex. Diaxonhit (Euronext:ALEHT), Paris, France   Product: BJI InoPlex   Business: Diagnostic   Molecular target: NA...
Items per page:
1 - 3 of 3